Care of the potential organ donor

New England Journal of Medicine

Volumn 351, Issue 26, 2004, Pages 2730-2739

  Wood, Kenneth E ^a,b   Becker, Bryan N ^a   McCartney, John G ^a   D'Alessandro, Anthony M ^a   Coursin, Douglas B ^a  

^a University of Wisconsin Health   (United States)

^b Department of Medicine ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYPERTENSIVE FACTOR; INSULIN; MANNITOL; VASOPRESSIN;

ADENOVIRUS; BACTEREMIA; BLOOD SAMPLING; BRAIN DEATH; BRAIN INJURY; CARDIOVASCULAR EFFECT; CLINICAL FEATURE; CYTOMEGALOVIRUS; DIABETES INSIPIDUS; ELECTROLYTE BLOOD LEVEL; ENTEROVIRUS; FUNGEMIA; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN T CELL LEUKEMIA VIRUS; HYPERNATREMIA; HYPOVOLEMIA; INSULIN TREATMENT; INTRACRANIAL PRESSURE; MEASLES; MENINGOENCEPHALITIS; ORGAN DONOR; ORGAN TRANSPLANTATION; PARVOVIRUS; PATIENT CARE; PRION DISEASE; PRIORITY JOURNAL; RABIES; RESPIRATORY FUNCTION; REVIEW;

BRAIN DEATH; CADAVER; HEMODYNAMIC PROCESSES; HORMONE REPLACEMENT THERAPY; HUMANS; RESPIRATION; THIRD-PARTY CONSENT; TISSUE AND ORGAN HARVESTING; TISSUE DONORS;

EID: 10844250318     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMra013103     Document Type: Review

References (74)

1. Sheehy E, Conrad SL, Brigham LE, et al. Estimating the number of potential organ donors in the United States. N Engl J Med 2003;349:667-74.
2. Gasser M, Waaga AM, Laskowski IA, Tilney NL. Organ transplantation from brain-dead donors: its impact on short and long term outcome revisited. Transplant Rev 2001;15:1-10.
3. Wijdicks EF. The diagnosis of brain death. N Engl J Med 2001;344:1215-21.
4. Idem. Brain death worldwide: accepted fact but no global consensus in diagnostic criteria. Neurology 2002;58:20-5.
5. Recommendations for nonheartbeating organ donation: a position paper by the Ethics Committee, American College of Critical Care Medicine, Society of Critical Care Medicine. Crit Care Med 2001;29:1826-31.
6. Angelis M, Cooper JT, Freeman RB. Impact of donor infections on outcome of orthotopic liver transplantation. Liver Transpl 2003;9:451-62.
7. Freeman RB, Giatras I, Falagas ME, et al. Outcome of transplantation of organs procured from bacteremic donors. Transplantation 1999;68:1107-11.
8. Lopez-Navidad A, Caballero F. Extended criteria for organ acceptance: strategies for achieving organ safety and increasing organ pool. Clin Transplant 2003;17:308-24.
9. Sarmento A, Freitas F, Tavares AP, Machado D. Organ donor viral screening and its implications in transplantation: an overview. Transplant Proc 2000;32:2571-6.
10. Kauffman HM, McBride MA, Delmonico FL. First report of the United Network for Organ Sharing Transplant Tumor Registry: donors with a history of cancer. Transplantation 2000;70:1747-51.
11. Kauffman HM, McBride MA, Cherikh WS, Spain PC, Marks WH, Roza AM. Transplant tumor registry: donor related malignancies. Transplantation 2002;74:358-62.
12. Buell JF, Trofe J, Sethuraman G, et al. Donors with central nervous system malignancies: are they truly safe? Transplantation 2003;76:340-3.
13. The Organ Donation Breakthrough Collaborative. Best practices final report (September 2003). (Accessed November 24, 2004, at http://www.organdonor. gov/bestpractice.htm.)
14. Gortmaker SL, Beasley CL, Sheehy E, et al. Improving the request process to increase family consent for organ donation. J Transpl Coord 1998;8:210-7.
15. Williams MA, Lipsett PA, Rushton CH, et al. The physician's role in discussing organ donation with families. Crit Care Med 2003;31:1568-73.
16. Nygaard CE, Townsend RN, Diamond DL. Organ donor management and organ outcome: a 6-year review from a Level I trauma center. J Trauma 1990;30:728-32.
17. Lopez-Navidad A, Domingo P, Viedma MA. Professional characteristics of the transplant coordinator. Transplant Proc 1997;29: 1607-13.
18. Grossman MD, Reilly PM, McMahon DJ, et al. Loss of potential organ donors due to medical failure. Crit Care Med 1996;24: A76. abstract.
19. Jenkins DH, Reilly PM, Schwab CW. Improving the approach to organ donation: a review. World J Surg 1999;23:644-9.
20. Lopez-Navidad A, Caballero F. For a rational approach to the critical points of the cadaveric donation process. Transplant Proc 2001;33:795-805.
21. Wheeldon DR, Potter CD, Oduro A, Wallwork J, Large SR, Transforming the "unacceptable" donor: outcomes from the adoption of a standardized donor management technique. J Heart Lung Transplant 1995;14:734-42.
22. Rosendale JD, Chabalewski FL, McBride MA, et al. Increased transplanted organs from the use of a standardized donor management protocol. Am J Transplant 2002;2: 761-8.
23. Wilhelm MJ, Pratschke J, Laskowski IA, Paz DM, Tilney NL. Brain death and its impact on the donor heart - lessons from animal models. J Heart Lung Transplant 2000;19:414-8.
24. Baroldi G, Di Pasquale G, Silver MD, Pinelli G, Lusa AM, Fineschi V. Type and extent of myocardial injury related to brain damage and its significance in heart transplantation: a morphometric study. J Heart Lung Transplant 1997;16:994-1000.
25. Novitzky D, Horak A, Cooper DK, Rose AG. Electrocardiographs and histopathologic changes developing during experimental brain death in the baboon. Transplant Proc 1989;21:2567-9.
26. Kolin A, Norris JW. Myocardial damage from acute cerebral lesions. Stroke 1984;15:990-3.
27. Shivalkar B, Van Loon J, Wieland W, et al. Variable effects of explosive or gradual increase of intracranial pressure on myocardial structure and function. Circulation 1993; 87:230-9.
28. Kono T, Nishina T, Morita H, Hirota Y, Kawamura K, Fujiwara A. Usefulness of low-dose dobutamine stress echocardiography for evaluating reversibility of brain death-induced myocardial dysfunction. Am J Cardiol 1999;84:578-82.
29. Milano A, Livi U, Casula R, et al. Influence of marginal donors on early results after heart transplantation. Transplant Proc 1993;25:3158-9.
30. Jenkins DH, Reilly PM, McMahon DJ, Hawthorne RV. Minimizing charges associated with the determination of brain death. Crit Care (Lond) 1997;1:65-70.
31. Potter CD, Wheeldon DR, Wallwork J. Functional assessment and management of heart donors: a rationale for characterization and a guide to therapy. J Heart Lung Transplant 1995;14:59-65.
32. Cantin B, Kwok BW, Chan MC, et al. The impact of brain death on survival after heart transplantation: time is of the essence. Transplantation 2003;76:1275-9.
33. Whelchel JD, Diethelm AG, Phillips MD, et al. The effect of high dose dopamine in cadaveric donor management on delayed graft function and graft survival following renal transplantation. Transplant Proc 1986; 18:523-7.
34. Finfer S, Bohn D, Colpitts D, Cox P, Fleming F, Barker G. Intensive care management of paediatric organ donors and its effect on post-transplant organ function. Intensive Care Med 1996;22:1424-32.
35. Power BM, Van Heerden PV. The physiological changes associated with brain death - current concepts and implications for treatment of the brain dead organ donor. Anaesth Intensive Care 1995;23:26-36.
36. Totsuka E, Fung JJ, Ishii T, et al. Influence of donor condition on postoperative graft survival and function in human liver transplantation. Transplant Proc 2000;32: 322-6.
37. Cittanova ML, Leblanc I, Legendre C, Mouquet C, Riou B, Coriat P. Effect of hydroxyethylstarch in brain-dead kidney donors on renal function in kidney-transplant recipients. Lancet 1996;348:1620-2.
38. Reilly PM, Grossman MD, Rosengard BR, et al. Lung procurement from solid organ donors: role of fluid resuscitation in procurement failures. Chest 1996;110:222S. abstract.
39. Pennefather SH, Bullock RE, Dark JH. The effect of fluid therapy on alveolar arterial oxygen gradient in brain-dead organ donors. Transplantation 1993;56:1418-22.
40. Rosengard BR, Feng S, Alfrey EJ, et al. Report of the Crystal City meeting to maximize the use of organs recovered from the cadaver donor. Am J Transplant 2002;2:701-11.
41. Koning OH, Ploeg RJ, van Bockel JH, et al. Risk factors for delayed graft function in cadaveric kidney transplantation: a prospective study of renal function and graft survival after preservation with University of Wisconsin solution in multi-organ donors. Transplantation 1997;63:1620-8.
42. Schnuelle P, Lorenz D, Mueller A, Trede M, van der Woude FJ. Donor catecholamine use reduces acute allograft rejection and improves graft survival after cadaveric renal transplantation. Kidney Int 1999;56:738-46.
43. Schnuelle P, Berger S, de Boer J, Persijn G, van der Woude FJ. Effects of catecholamine application to brain-dead donors on graft survival to solid organ transplantation. Transplantation 2001;72:455-63.
44. Tilney NL, Paz D, Ames J, Gasser M, Laskowski I, Hancock WW. Ischemia-reperfusion injury. Transplant Proc 2001;33: 843-4.
45. Amado JA, Lopez-Espadas F, Vazquez-Barquero A, et al. Blood levels of cytokines in brain-dead patients: relationship with circulating hormones and acute-phase reactants. Metabolism 1995;44:812-6.
46. Stangl M, Zerkaulen T, Theodorakis J, et al. Influence of brain death on cytokine release in organ donors and renal transplants. Transplant Proc 2001;33:1284-5.
47. Ueno T, Zh-Li C, Itoh T. Unique circulatory responses to exogenous catecholamines after brain death. Transplantation 2000;70: 436-40.
48. Pennefather SH, Bullock RE, Mantle D, Dark JH. Use of low dose arginine vasopressin to support brain-dead organ donors. Transplantation 1995;59:58-62.
49. Yoshioka T, Sugimoto H, Uenishi M, et al. Prolonged hemodynamic maintenance by the combined administration of vasopressin and epinephrine in brain death: a clinical study. Neurosurgery 1986;18:565-7.
50. Marik PE, Zaloga GP. Adrenal insufficiency in the critically ill: a new look at an old problem. Chest 2002;122:1784-96.
51. Lutz-Dettinger N, de Jaeger A, Kerremans I. Care of the potential pediatric organ donor. Pediatr Clin North Am 2001;48: 715-49.
52. Novitzky D. Donor management: state of the art. Transplant Proc 1997;29:3773-5.
53. Cooper DK, Novitzky D, Wicomb WN. The pathophysiological effects of brain death on potential donor organs, with particular reference to the heart. Ann R Coll Surg Engl 1989;71:261-6.
54. Novitzky D, Cooper DK, Reichart B. Hemodynamic and metabolic responses to hormonal therapy in brain-dead potential organ donors. Transplantation 1987;43: 852-4.
55. Novitzky D, Cooper DK, Morrell D, Isaacs S. Change from aerobic to anaerobic metabolism after brain death, and reversal following triiodothyronine therapy. Transplantation 1988;45:32-6.
56. Howlett TA, Keogh AM, Perry L, Touzel R, Rees LH. Anterior and posterior pituitary function in brain-stem-dead donors: a possible role for hormonal replacement therapy. Transplantation 1989;47:828-34.
57. Powner DJ, Hendrich A, Lagler RG, Ng RH, Madden RL. Hormonal changes in brain dead patients. Crit Care Med 1990;18: 702-8.
58. Gramm HJ, Meinhold H, Bickel U, et al. Acute endocrine failure after brain death? Transplantation 1992;54:851-7.
59. Randell TT, Hockerstedt KA. Triiodothyronine treatment in brain-dead multiorgan donors - a controlled study. Transplantation 1992;54:736-8.
60. Goarin JP, Cohen S, Riou B, et al. The effects of triiodothyronine on hemodynamic status and cardiac function in potential heart donors. Anesth Analg 1996;83:41-7.
61. Salim A, Vassiliu P, Velmahos GC, et al. The role of thyroid hormone administration in potential organ donors. Arch Surg 2001; 136:1377-80.
62. Rosendale JD, Kauffman HM, McBride MA, et al. Aggressive pharmacologic donor management results in more transplanted organs. Transplantation 2003;75:482-7.
63. Novitzky D, Wicomb WN, Rose AG, Cooper DK, Reichart B. Pathophysiology of pulmonary edema following experimental brain death in the chacma baboon. Ann Thorac Surg 1987;43:288-94.
64. Gabbay E, Williams TJ, Griffiths AP, et al. Maximizing the utilization of donor organs offered for lung transplantation. Am J Respir Crit Care Med 1999;160:265-71.
65. Follette D, Rudich S, Bonacci C, Allen R, Hoso A, Albertson T. Importance of an aggressive multidisciplinary management approach to optimize lung donor procurement Transplant Proc 1999;31:169-70.
66. Parry A, Higgins R, Wheeldon D, Bethune D, Wallwork J. The contribution of donor management and modified cold blood lung perfusate to post-transplant lung function. J Heart Lung Transplant 1999;18:121-6.
67. Cummings J, Houck J, Lichtenfeld D. Positive effect of aggressive resuscitative efforts on cadaver lung procurement. J Transplant Coordination 1995;5:103-6.
68. Sakuma T, Folkesson HG, Suzuki S, Okaniwa G, Fujimura S, Matthay MA. Betaadrenergic agonist stimulated alveolar fluid clearance in ex vivo human and rat lungs. Am J Respir Crit Care Med 1997;155:506-12.
69. Follette DM, Rudich SM, Babcock WD. Improved oxygenation and increased lung donor recovery with high-dose steroid administration after brain death. J Heart Lung Transplant 1998;17:423-9.
70. Sundaresan S, Semenkovich J, Ochoa L, et al. Successful outcome of lung transplantation is not compromised by the use of marginal donor lungs. J Thorac Cardiovasc Surg 1995;109:1075-9.
71. Richardson DW, Robinson AG. Desmopressin. Ann Intern Med 1985;103:228-39.
72. Masson F, Thicoipe M, Gin H, et al. The endocrine pancreas in brain-dead donors: a prospective study in 25 patients. Transplantation 1993;56:363-7.
73. Gores PF, Gillingham KJ, Dunn DL, Moudry-Munns KC, Najarian JS, Sutherland DE. Donor hyperglycemia as a minor risk factor and immunologic variables as major risk factors for pancreas allograft loss in a multivariate analysis of a single institution's experience. Ann Surg 1992;215:217-30.
74. Hefty TR, Cotterell LW, Fraser SC, Goodnight SH, Hatch TR. Disseminated intravascular coagulation in cadaveric organ donors: incidence and effect on renal transplantation. Transplantation 1993;55:442-3.